AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

Acceleron to Webcast Fourth Quarter and Full Year 2018 Operating and Financial Results on February 27, 2019

February 19, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 19, 2019--Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Wednesday, February 27, 2019 at 5:00 p.m. EST to discuss its fourth quarter and full year 2018 operating and financial results.

The webcast will be accessible under “Events & Presentations” in the Investors/Media page of the company’s website at www.acceleronpharma.com. Individuals can participate in the conference call by dialing 877-312-5848 (domestic) or 253-237-1155 (international) and refer to the “Acceleron Fourth Quarter and Full Year 2018 Earnings Call.”

The archived webcast will be available for replay on the Acceleron website approximately two hours after the event.

About Acceleron

Acceleron is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The Company’s leadership in the understanding of TGF-beta biology and protein engineering generates innovative compounds that engage the body’s ability to regulate cellular growth and repair.

Acceleron focuses its research and development efforts in hematologic, neuromuscular, and pulmonary diseases. In hematology, the Company and its global collaboration partner, Celgene, are developing luspatercept for the treatment of chronic anemia in myelodysplastic syndromes, beta-thalassemia, and myelofibrosis. Acceleron is also advancing its neuromuscular franchise with two distinct Myostatin+ agents, ACE-083 and ACE-2494, and a Phase 2 pulmonary program with sotatercept in pulmonary arterial hypertension.

For more information, please visit  www.acceleronpharma.com. Follow Acceleron on social media:  @AcceleronPharma and LinkedIn.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190219005143/en/

CONTACT: Acceleron Pharma Inc.

Investors:

Todd James, IRC, (617) 649-9393

Vice President, Investor Relations and Corporate Communications

or

Media:

Matt Fearer, (617) 301-9557

Director, Corporate Communications

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL RESEARCH SCIENCE

SOURCE: Acceleron Pharma Inc.

Copyright Business Wire 2019.

PUB: 02/19/2019 07:00 AM/DISC: 02/19/2019 07:01 AM

http://www.businesswire.com/news/home/20190219005143/en